Diffuse Large B-cell Lymphoma, Peripheral T Cell Lymphoma
Conditions
Keywords
aggressive non-Hodgkin's lymphoma (NHL), Mitoxantrone hydrochloride liposome, GVM±R
Brief summary
This is a prospective clinical study to evaluate the safety and efficacy of GVM±R in patients with relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL).
Detailed description
This is a single-arm, open label, multi-center clinical study to evaluate the safety and efficacy of mitoxantrone hydrochloride liposome in combination with gemcitabine, vinorelbine and/or anti-CD20 monoclonal antibody(GVM ± R) in patients with relapsed or refractory aggressive non-Hodgkin lymphoma (NHL).Mitoxantrone hydrochloride liposome will be given on day 1 at dose of 18 mg/m2 and be combined with gemcitabine, vinorelbine and/or rituximab (Pts with CD20-positive lymphomas are evaluated by the investigator on whether to combine rituximab or choose another CD20 monoclonal antibody).Each cycle consists of 21 days. A maximum of 6 cycles of therapy are planned.
Interventions
DRUGGVM±R regimen
Mitoxantrone hydrochloride liposome (18 mg/m\^2) on day 1； Gemcitabine (800 mg/m\^2) on day 1,8； Vinorelbine (20mg/m\^2) on day 1,8； Rituximab (375mg/m\^2) on day 1; The regimen will be administered every 3 weeks, for a maximum of 6 cycles. The choice of CD20 monoclonal antibody will be determined by the attending physician.
Sponsors
First Hospital of China Medical University
Hebei Medical University Fourth Hospital
Chengdu Shangjin Nanfu Hospital
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Xuanwu Hospital, Beijing
The Affiliated Ganzhou Hospital of Nanchang University
Beijing Tongren Hospital
The First Affiliated Hospital of Dalian Medical University
The First Hospital of Jilin University
People's Hospital of Zhengzhou University
The First Affiliated Hospital of Bengbu Medical University
The Second Affiliated Hospital of Kunming Medical University
The First Affiliated Hospital of Nanchang University
The Second Affiliated Hospital of Harbin Medical University
Shengjing Hospital
Peking University Third Hospital
First Affiliated Hospital of Harbin Medical University
China-Japan Friendship Hospital
Institute of Hematology & Blood Diseases Hospital, China
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Age ≥18, ≤65 years. 2. Expected survival ≥ 3 months. 3. Subjects with aggressive NHL who have relapsed or proven refractory to at least one line of standard therapy or have achieved PR as the best response after a minimum of 4 cycles of therapy (patients with a Deauville score of 4 must have biopsy-proven residual disease). Relapse is defined as a disease response (PR/CR) to the last-line therapy with a duration of response exceeding 6 months. Refractory disease can be confirmed under any of the following conditions: 1) no partial or complete response to the last-line therapy; 2) the duration of complete or partial response to the last-line therapy is no longer than 6 months from the last dose of therapy; 3) Recurrence after hematopoietic stem cell transplantation. 4. Subjects must have at least one measurable lesion per lugano2014 criteria: for lymph node lesions, the long diameter should be \> 1.5cm; For non-lymph node lesions, the long diameter should be \> 1.0cm; 5. Eastern Cooperative Oncology Group (ECOG) : 0-2 6. Peripheral blood: Absolute neutrophil count (ANC) ≥1.5×109/L, Platelet count (PLT) ≥75×109/L, Hemoglobin(HB)≥ 80g/L.(Restriction may be relaxed in patients with bone marrow involvement, Absolute neutrophil count (ANC) ≥1.0×109/L, Platelet count (PLT) ≥50×109/L, Hemoglobin(HB)≥ 75g/L). 7. Liver and kidney function: Serum creatinine (Scr) ≤1.5X upper limit of normal (ULN).Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5X ULN, Total bilirubin (TBIL) ≤1.5X upper limit of normal (ULN).(If the lymphoma involves the liver, TBIL≤3 X ULN.AST and ALT≤5 X ULN). For Pts diagnosed with Gilbert's disease, TBIL was enrolled if it was ≤3 X ULN.-
Exclusion criteria
1. The subject had previously received any of the following anti-tumor treatments: 1. Subjects who have been treated with mitoxantrone or mitoxantrone liposomes; 2. Previously received doxorubicin or other anthracycline treatment, and the total cumulative dose of doxorubicin was more than 360 mg/m2 (For other anthracyclines, 1 mg doxorubicin equivalent to 2 mg epirubicin); 3. Subjects who received anti-tumor treatment (including chemotherapy, targeted therapy, glucocorticoid, traditional Chinese medicine with anti-tumor activity, etc.) or participated in other clinical trials and received trial drugs within 4 weeks or 5 half-lives((whichever comes first) before the first administration of the study drugs; 4. Subjects who received autologous hematopoietic stem cell transplantation or allogeneic hematopoietic stem cell transplantation within 100 days before the first administration of study drugs; 5. Subjects who received chimeric antigen receptor T-cell (CAR-T) therapy. 2. Hypersensitivity to any study drug or its components. 3. Uncontrolled systemic diseases (such as active infection, uncontrolled hypertension, diabetes, etc.) 4. Heart function and disease meet one of the following conditions: 1. Long QTc syndrome or QTc interval \> 480 ms; 2. Complete left bundle branch block, grade II or III atrioventricular block; 3. Serious and uncontrolled arrhythmias requiring drug treatment; 4. New York Heart Association grade ≥ III; 5. Left Ventricular Ejection Fractions (LVEF)\< 50%; 6. A history of myocardial infarction, unstable angina pectoris, severe unstable ventricular arrhythmia or any other arrhythmia requiring treatment, a history of clinically serious pericardial disease, or ECG evidence of acute ischemia or active conduction system abnormalities within 6 months before recruitment. 5. Active hepatitis B and C infection (defined as hepatitis B virus surface antigen positive and hepatitis B virus DNA higher than the Upper limit of normal(ULN); Hepatitis C virus antibody positive and hepatitis C virus RNA higher than the Upper limit of normal). 6. Human immunodeficiency virus (HIV) infection (defined as HIV antibody positive). 7. Patients with other malignant tumors, except for effectively controlled non-melanoma skin basal cell carcinoma, breast/cervical carcinoma in situ or other tumors without treatment during the past 5 years. 8. Pregnant and lactating women and patients of childbearing age who are unwilling to take contraceptive measures. 9. ≥ Grade 3 neuritis. 10. Active central nervous system (CNS) lymphoma; 11. Unsuitable subjects for this study determined by the investigator. -
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Response Rate (ORR) | up to 2 years | Response is assessed according to the lugano criteria |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Complete Response Rate (CRR) | up to 2 years | Response is assessed according to the lugano criteria |
| Progression-Free-Survival (PFS) | up to 2 years | From the date of the first dose of therapy is given until disease progression, death or last follow-up |
| Overall survival (OS) | up to 2 years | From the date of inclusion to date of death, irrespective of cause |
| Incidence of Treatment-Emergent Adverse Events | up to 2 years | The adverse events were evaluated by NCI-CTCAE 5.0 standard Hematologic and non-hematologic toxicity |
Countries
China
Contacts
Primary ContactWei Liu
Outcome results
None listed